# Study of Lamotrigine 2 x 25 mg IR Tablets of Torrent Pharmaceuticals Pvt., Ltd., India and Lamictal ® (Lamotrigine) 2 x 25 mg Tablets of Glaxo-SmithKline, USA, in Healthy Human Adult Subjects, Under Fed Conditions

> **NCT00939458** · PHASE1 · COMPLETED · sponsor: **Torrent Pharmaceuticals Limited**

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Lamotrigine

## Key facts

- **NCT ID:** NCT00939458
- **Lead sponsor:** Torrent Pharmaceuticals Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2017-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00939458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00939458, "Study of Lamotrigine 2 x 25 mg IR Tablets of Torrent Pharmaceuticals Pvt., Ltd., India and Lamictal ® (Lamotrigine) 2 x 25 mg Tablets of Glaxo-SmithKline, USA, in Healthy Human Adult Subjects, Under Fed Conditions". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00939458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*